Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Alimera Sciences, Inc. (ALIM)

1.4   0 (0%) 03-24 11:11
Open: 1.4 Pre. Close: 1.4
High: 1.4 Low: 1.38
Volume: 3,842 Market Cap: 10(M)

Technical analysis

as of: 2023-03-24 10:41:36 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.49     One year: 3.08
Support: Support1: 1.33    Support2: 1.1
Resistance: Resistance1: 2.13    Resistance2: 2.64
Pivot: 1.73
Moving Average: MA(5): 1.49     MA(20): 1.83
MA(100): 2.91     MA(250): 4.62
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 6.6     %D(3): 12.6
RSI: RSI(14): 27.5
52-week: High: 7.92  Low: 1.33
Average Vol(K): 3-Month: 12 (K)  10-Days: 10 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALIM ] has closed above bottom band by 16.7%. Bollinger Bands are 4.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.46 - 1.47 1.47 - 1.48
Low: 1.4 - 1.41 1.41 - 1.42
Close: 1.41 - 1.42 1.42 - 1.44

Company Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Headline News

Thu, 23 Mar 2023
Do Traders Think Alimera Sciences Inc (ALIM) Can Turn Around Thursday? - InvestorsObserver

Thu, 23 Mar 2023
North American Morning Briefing : Traders Reassess -2- -

Thu, 16 Mar 2023
North American Morning Briefing: Some Calm -2- - Morningstar

Mon, 27 Feb 2023
Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors - GlobeNewswire

Wed, 22 Feb 2023
Alimera Announces Submission of Marketing Authorization ... - GlobeNewswire

Mon, 09 Jan 2023
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as ... - GlobeNewswire

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 7 (M)
Shares Float 5 (M)
% Held by Insiders 20 (%)
% Held by Institutions 32.4 (%)
Shares Short 23 (K)
Shares Short P.Month 25 (K)

Stock Financials

EPS -2.44
EPS Est Next Qtl -0.02
EPS Est This Year -0.21
EPS Est Next Year -0.08
Book Value (p.s.) -5.33
Profit Margin (%) -34.1
Operating Margin (%) -22.8
Return on Assets (ttm) -14.9
Return on Equity (ttm) 0
Qtrly Rev. Growth 11.8
Gross Profit (p.s.) 7.41
Sales Per Share 7.71
EBITDA (p.s.) -1.37
Qtrly Earnings Growth 0
Operating Cash Flow -14 (M)
Levered Free Cash Flow -8 (M)

Stock Valuations

PE Ratio -0.58
PEG Ratio 0
Price to Book value -0.27
Price to Sales 0.18
Price to Cash Flow -0.69

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-11-14
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.